WO2010104485A3 - Valsartan formulations - Google Patents

Valsartan formulations Download PDF

Info

Publication number
WO2010104485A3
WO2010104485A3 PCT/TR2010/000046 TR2010000046W WO2010104485A3 WO 2010104485 A3 WO2010104485 A3 WO 2010104485A3 TR 2010000046 W TR2010000046 W TR 2010000046W WO 2010104485 A3 WO2010104485 A3 WO 2010104485A3
Authority
WO
WIPO (PCT)
Prior art keywords
valsartan
formulations
valsartan formulations
active agent
microcrystalline cellulose
Prior art date
Application number
PCT/TR2010/000046
Other languages
French (fr)
Other versions
WO2010104485A2 (en
Inventor
Umit Cifter
Ali Turkyilmaz
Hasan Ali Turp
Original Assignee
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi filed Critical Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
Priority to EP10726655A priority Critical patent/EP2405899A2/en
Publication of WO2010104485A2 publication Critical patent/WO2010104485A2/en
Publication of WO2010104485A3 publication Critical patent/WO2010104485A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Abstract

The present invention relates to a new pharmaceutical formulation in the form of a tablet consisting of valsartan as an active agent, pregelatinized starch, microcrystalline cellulose.
PCT/TR2010/000046 2009-03-11 2010-03-10 Valsartan formulations WO2010104485A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP10726655A EP2405899A2 (en) 2009-03-11 2010-03-10 Valsartan formulations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR200901901 2009-03-11
TRTR2009/01901 2009-03-11

Publications (2)

Publication Number Publication Date
WO2010104485A2 WO2010104485A2 (en) 2010-09-16
WO2010104485A3 true WO2010104485A3 (en) 2010-11-25

Family

ID=41226269

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2010/000046 WO2010104485A2 (en) 2009-03-11 2010-03-10 Valsartan formulations

Country Status (2)

Country Link
EP (1) EP2405899A2 (en)
WO (1) WO2010104485A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013191668A1 (en) * 2012-06-22 2013-12-27 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Compositions preventing hypertension comprising soluplus

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006066961A1 (en) * 2004-12-24 2006-06-29 Krka, D.D., Novo Mesto Solid pharmaceutical composition comprising valsartan
WO2007022113A2 (en) * 2005-08-17 2007-02-22 Novartis Ag Solid dosage forms of valsartan and amlodipine and method of making the same
WO2007026261A2 (en) * 2005-05-18 2007-03-08 Combino Pharm, S.L. Formulations containing losartan and/or its salts
WO2007049292A1 (en) * 2005-10-27 2007-05-03 Lupin Limited Pharmaceutical formulation of losartan
WO2007049291A1 (en) * 2005-10-27 2007-05-03 Lupin Limited Novel solid dosage forms of valsartan and rochlorothiazide
WO2007052307A2 (en) * 2005-10-31 2007-05-10 Lupin Limited Stable solid oral dosage forms of valsartan

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK117996A3 (en) 1994-03-17 1997-03-05 Ciba Geigy Ag Pharmaceutical composition for treatment of diabetic nephropathy
GB9613470D0 (en) 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
NZ553010A (en) 1998-12-23 2008-09-26 Novartis Ag Use of AT-1 receptor antagonist or AT-2 receptor modulator for treating diseases associated with an increase of AT-1 or AT-2 receptors
SK50472005A3 (en) 2003-11-03 2005-09-08 Zentiva, A. S. Tablet containing valsartan prepared via direct tabletting
TR200703568A1 (en) * 2007-05-24 2008-07-21 Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� Valsartan formulations

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006066961A1 (en) * 2004-12-24 2006-06-29 Krka, D.D., Novo Mesto Solid pharmaceutical composition comprising valsartan
WO2007026261A2 (en) * 2005-05-18 2007-03-08 Combino Pharm, S.L. Formulations containing losartan and/or its salts
WO2007022113A2 (en) * 2005-08-17 2007-02-22 Novartis Ag Solid dosage forms of valsartan and amlodipine and method of making the same
WO2007049292A1 (en) * 2005-10-27 2007-05-03 Lupin Limited Pharmaceutical formulation of losartan
WO2007049291A1 (en) * 2005-10-27 2007-05-03 Lupin Limited Novel solid dosage forms of valsartan and rochlorothiazide
WO2007052307A2 (en) * 2005-10-31 2007-05-10 Lupin Limited Stable solid oral dosage forms of valsartan

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2405899A2 *

Also Published As

Publication number Publication date
EP2405899A2 (en) 2012-01-18
WO2010104485A2 (en) 2010-09-16

Similar Documents

Publication Publication Date Title
CL2013001586A1 (en) Rapid dispersion microgranular composition comprising at least one sugar alcohol, a saccharide, or a mixture thereof, at least one super disintegrant and at least one multifunctional additive; oral disintegration tablet comprising the microgranular composition and at least one active ingredient; and manufacturing methods.
WO2011120904A3 (en) A fast dissolving pharmaceutical composition
PL2808325T3 (en) Substituted azoles, anti-viral active ingredient, pharmaceutical composition, method for the production and use thereof
MX342440B (en) Fluorinated aminotriazole derivatives.
WO2011012816A3 (en) Pharmaceutical formulation
WO2011009938A3 (en) Stambomycin and derivatives, their production and their use as drugs
WO2013175221A3 (en) Composition
WO2011104652A3 (en) Veterinary compositions
WO2011076212A3 (en) Processes for the manufacture of a pharmaceutically active agent
PL1994926T3 (en) Valsartan formulations
WO2011037976A3 (en) Pramipexole pharmaceutical formulations
WO2011079193A3 (en) Preparation of bendamustine and its salts
WO2010049449A3 (en) Novel salts of sunitinib
WO2008129501A3 (en) Pharmaceutical compositions of duloxetine
WO2011120903A3 (en) A fast dissolving pharmaceutical composition
WO2011142731A3 (en) Formulations comprising a third generation cephalosporin and clavulanic acid
WO2010082689A3 (en) Gip-increase inhibitor
EP2498818B8 (en) Microcrystalline cellulose and calcium phosphate compositions useful as pharmaceutical excipients
WO2011135581A3 (en) Pharmaceutical compositions of dronedarone
MX2011006721A (en) Pharmaceutical formulation of nanonised fenofibrate.
WO2011156045A3 (en) Tablet formulation of ezatiostat
WO2011006596A3 (en) Aqueous solution and gelatinized composition comprising a phosphodiesterase-5 inhibitor and corresponding methods and use
WO2011064797A3 (en) Controlled release pharmaceutical compositions of galantamine
WO2010104485A3 (en) Valsartan formulations
WO2012016646A9 (en) Quetiapine tablets

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10726655

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2011/08842

Country of ref document: TR

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2010726655

Country of ref document: EP